poster

(#97) Long-Term Safety of Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Schizophrenia: Results From the Phase 3 SOLARIS Trial

Abstract: TV-44749 is an innovative, subcutaneous long-acting injectable (LAI) olanzapine designed to provide sustained efficacy over the dosing interval without the post-injection deliri...

04/20/2026

(#98) Estimation of the Minimal Clinically Important Difference (MCID) and Longitudinal Change in the Tardive Dyskinesia Impact Scale (TDIS), a Validated, Tardive Dyskinesia-Specific, Patient-Reported Outcome Measure

Abstract: Tardive Dyskinesia Impact Scale (TDIS) evaluates TD symptom impact over the previous 7 days and was a KINECT®3, KINECT®4, and KINECT-PRO outcome. Objectives were to estimate min...

04/20/2026

(#99) Social Determinants of Health among Patients with Experiential Negative Symptoms Living with Schizophrenia: Medical Expenditure Panel Survey

Abstract: Background: Experiential negative symptoms (ENS) of schizophrenia include avolition, asociality, and anhedonia, which impact quality of life and functioning. This study assessed...

04/20/2026

(#91) Antipsychotic Medication Utilization and Treatment Patterns Among Patients With Schizophrenia: A Real-World Evidence Study

Abstract: Rationale: This study assessed treatment patterns and adherence among patients with a diagnosis of schizophrenia receiving antipsychotic medications.

04/20/2026

(#92) A Conceptual Model For Assessing Psychosocial Functioning In People Living With Schizophrenia

Abstract: INTRODUCTION:Schizophrenia is a serious mental health disorder impacting all aspects of life in people living with schizophrenia (PLS), many of whom have a limited response to c...

04/20/2026

(#93) Antihostility Effects of Xanomeline and Trospium Chloride in Subjects With Schizophrenia: Post Hoc Pooled Analyses of EMERGENT-1, EMERGENT-2, and EMERGENT-3 Trials

Abstract: Background: In addition to hallucinations and delusions, people with schizophrenia may exhibit hostility, which is associated with aggressive and violent behavior during acute e...

04/20/2026

(#94) Population pharmacokinetics and dosing simulations for alternative maintenance doses of 351 mg LY03010 (paliperidone palmitate) in patients with schizophrenia or schizoaffective disorder

Abstract: LY03010 (brand name ERZOFRI®) is a newly approved once-a-month paliperidone palmitate (PP1M) extended-release injectable suspension with a differentiated single initial injectio...

04/20/2026

(#95) Evaluating Long-Term Weight Gain and Other Metabolic Changes With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Results From the Phase 3 SOLARIS Trial

Abstract: TV-44749 is an innovative, subcutaneous, long-acting injectable olanzapine for treatment of schizophrenia, designed to provide sustained efficacy and eliminate the risk of post-...

04/20/2026

(#96) Long-Term Effectiveness With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Results From up to 48 Weeks Open Label Treatment in the Phase 3 SOLARIS Trial

Abstract: Long-acting injectable (LAI) antipsychotics improve adherence and outcomes in adults with schizophrenia. Olanzapine is available as an intramuscular LAI; however, post-injection...

04/20/2026

(#87) Comparative analysis of relapse rates with paliperidone palmitate 6-month in patients with schizophrenia: randomized controlled trial vs matched real-world data

Abstract: Background: Paliperidone palmitate (PP) 6-month (PP6M) is the longest-acting injectable antipsychotic approved for the treatment of adult schizophrenia patients adequately stabi...

04/20/2026

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia-Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.